Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.
Cancer chemotherapy
EORTC QLQ-C30
Health-related quality of life
Pancreatic Cancer
Performance status
Journal
BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
24
01
2020
accepted:
30
06
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
23
3
2021
Statut:
epublish
Résumé
Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). Therefore, in addition to objective measures of effectiveness, the evaluation of health-related QoL should be considered a matter of major concern when assessing therapy outcomes. Observational, prospective, multicenter study including patients with metastatic pancreatic adenocarcinoma who started first-line chemotherapy in 12 Spanish centers. Treatment and clinical characteristics were recorded at baseline. Patients' health-related quality of life, ECOG, and Karnofsky index were measured at baseline, at Days 15 and 30, and every four weeks up to 6 months of chemotherapy. Health-related quality of life was measured using the EORTC-QLQ-C30 and EQ-5D questionnaires. Other endpoints included overall survival and progression-free survival. The study sample included 116 patients (median age of 65 years). Mean (SD) scores for the QLQ-C30 global health status scale showed a significant increasing trend throughout the treatment (p = 0.005). Patients with either a Karnofsky index of 70-80 or ECOG 2 showed greater improvement in the QLQ-C30 global health status score than the corresponding groups with better performance status (p ≤ 0.010). Pain, appetite, sleep disturbance, nausea, and constipation significantly improved throughout the treatment (p < 0.005). Patients with QLQ-C30 global health status scores ≥50 at baseline had significantly greater overall survival and progression-free survival (p = 0.005 and p = 0.021, respectively). No significant associations were observed regarding the EQ-5D score. Most metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy showed an increase in health-related quality of life scores throughout the treatment. Patients with lower performance status and health-related quality of life at baseline tended to greater improvement. The EORTC QLQ-C30 scale allowed us to measure the health-related quality of life of metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). Therefore, in addition to objective measures of effectiveness, the evaluation of health-related QoL should be considered a matter of major concern when assessing therapy outcomes.
METHODS
METHODS
Observational, prospective, multicenter study including patients with metastatic pancreatic adenocarcinoma who started first-line chemotherapy in 12 Spanish centers. Treatment and clinical characteristics were recorded at baseline. Patients' health-related quality of life, ECOG, and Karnofsky index were measured at baseline, at Days 15 and 30, and every four weeks up to 6 months of chemotherapy. Health-related quality of life was measured using the EORTC-QLQ-C30 and EQ-5D questionnaires. Other endpoints included overall survival and progression-free survival.
RESULTS
RESULTS
The study sample included 116 patients (median age of 65 years). Mean (SD) scores for the QLQ-C30 global health status scale showed a significant increasing trend throughout the treatment (p = 0.005). Patients with either a Karnofsky index of 70-80 or ECOG 2 showed greater improvement in the QLQ-C30 global health status score than the corresponding groups with better performance status (p ≤ 0.010). Pain, appetite, sleep disturbance, nausea, and constipation significantly improved throughout the treatment (p < 0.005). Patients with QLQ-C30 global health status scores ≥50 at baseline had significantly greater overall survival and progression-free survival (p = 0.005 and p = 0.021, respectively). No significant associations were observed regarding the EQ-5D score.
CONCLUSIONS
CONCLUSIONS
Most metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy showed an increase in health-related quality of life scores throughout the treatment. Patients with lower performance status and health-related quality of life at baseline tended to greater improvement. The EORTC QLQ-C30 scale allowed us to measure the health-related quality of life of metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy.
Identifiants
pubmed: 32650765
doi: 10.1186/s12904-020-00610-4
pii: 10.1186/s12904-020-00610-4
pmc: PMC7350578
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103Subventions
Organisme : Celgene (Spain)
ID : NA
Références
Qual Life Res. 2016 Jul;25(7):1713-23
pubmed: 26615615
J Clin Oncol. 2013 Jan 1;31(1):23-9
pubmed: 23213101
J Clin Oncol. 2010 Aug 1;28(22):3617-22
pubmed: 20606091
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Oncol. 2002 Jul 15;20(14):3130-6
pubmed: 12118027
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Med Clin (Barc). 1999;112 Suppl 1:79-85
pubmed: 10618804
Br J Cancer. 2002 Jul 15;87(2):161-7
pubmed: 12107836
J Gastrointest Cancer. 2015 Sep;46(3):201-11
pubmed: 25972062
Pancreatology. 2016 Nov - Dec;16(6):1106-1112
pubmed: 27600995
J Pain Symptom Manage. 2012 Feb;43(2):205-17
pubmed: 22104618
J Gastrointest Cancer. 2017 Mar;48(1):103-109
pubmed: 28028766
Pancreas. 2013 Mar;42(2):254-9
pubmed: 22850626
J Clin Oncol. 2014 Apr 20;32(12):1277-80
pubmed: 24638016
Lancet. 2008 Jun 21;371(9630):2101-8
pubmed: 18514303
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Int J Gastrointest Cancer. 2006;37(1):35-44
pubmed: 17290079
J Gastroenterol Hepatol. 2016 Mar;31(3):685-90
pubmed: 26412310
J Clin Oncol. 2010 Aug 1;28(22):3605-10
pubmed: 20606093
Crit Rev Oncol Hematol. 2016 Mar;99:286-98
pubmed: 26819138
J Oncol Pract. 2015 Mar;11(2):e216-21
pubmed: 25563703
Value Health. 2007 Nov-Dec;10 Suppl 2:S138-45
pubmed: 17995472
Pancreas. 2011 Oct;40(7):1063-9
pubmed: 21785386
J Gastrointest Oncol. 2014 Dec;5(6):433-9
pubmed: 25436122
Clin Transl Oncol. 2017 Nov;19(11):1293-1302
pubmed: 28612201
J Clin Oncol. 2006 Aug 20;24(24):3946-52
pubmed: 16921047
Eur J Cancer. 2009 Jun;45(9):1589-96
pubmed: 19188061
Eur J Cancer. 2018 Mar;92:20-32
pubmed: 29413686
J Clin Oncol. 2003 Sep 1;21(17):3296-302
pubmed: 12947065
Curr Probl Cancer. 2018 Jan - Feb;42(1):26-39
pubmed: 29631711
Br J Cancer. 2010 Oct 26;103(9):1318-24
pubmed: 20877359
Psychooncology. 2002 May-Jun;11(3):249-56
pubmed: 12112486